Thymosin Beta-4 (TB4) / TB-500 (fragment)

TB4 has animal wound-healing data and has been evaluated in human wound indications (e.g., venous stasis ulcers). TB-500 is a synthetic fragment; direct clinical evidence for TB-500 itself is limited.

research-chemicalpeptidewound-healingangiogenesis

Dosing model

FLATFixed dose (no body-weight scaling).

Min dose

—

Max dose

—

Rounding

—

Buy this ingredient ← Back

Stacks containing Thymosin Beta-4 (TB4) / TB-500 (fragment)

Public community stacks that include this ingredient.

Explore all stacks →

No public stacks include this ingredient yet.

Evidence

3 records

Wound healing acceleration (preclinical)

Rat full-thickness wound model • Controlled animal study

Low

In a rat wound model, TB4 increased re-epithelialization and improved contraction versus saline controls, supporting a wound-healing mechanism in animals.

Dose: — • Duration: Days (animal wound follow-up)

Citation: Malinda et al., (1999) — Thymosin beta4 accelerates wound healing

Wound healing (clinical development)

Patients with venous stasis ulcers • Registered phase 2 trial (TB4 gel)

Low

TB4 gel has been studied in venous stasis ulcer indications; registry evidence supports clinical testing, though effect sizes depend on the specific trial and endpoint reporting.

Dose: — • Duration: Up to 84 days (per registry)

Citation: ClinicalTrials.gov NCT00832091 — Thymosin Beta 4 in Venous Stasis Ulcers

Wound healing (reviewed clinical context)

Stasis and pressure ulcer clinical programs • Review article

Low

A review summarizes phase 2 wound-healing programs reporting faster healing in those that did heal; note that these are not sports injury RCTs.

Dose: —

Citation: Treadwell et al., (2012) — The regenerative peptide thymosin β4 accelerates…

Forms

Peptide (TB4)

Naturally occurring peptide studied in animals and humans.

Peptide fragment (TB-500)

Fragment derived from TB4 active region; less direct clinical documentation.